SEARCH

SEARCH BY CITATION

Fig. S1. rsCD40L enhanced cancer cells to doxorubicin-, etopside-, or paclitaxel-induced cell death.

Table S1. The combination effect of rsCD40L with cisplatin in SKOV3 cells was quantitatively evaluated using combination index (CI) analysis.

FilenameFormatSizeDescription
CAS_2122_sm_fS1.tif2410KSupporting info item
CAS_2122_sm_tS1.doc29KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.